Stay updated with breaking news from Robert Habib. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEWS RELEASE April 4, 2024 Announcement of Research Alliance with MiNA Therapeutics in the Field of Central Nervous...
Collaboration includes licensing agreement options based on early-stage clinical outcomes MiNA Therapeutics, the pioneer of small activating RNA (RNAa) therapeutics, today announced a multi-target research
Findings validate clinical proof of mechanism of MTL-CEBPA as a combination therapy in solid tumor cancers Company to initiate out-licensing activities of its immuno-oncology portfolio, including
Susan Clement-Davies and Professor Sir Robert Lechler join the Board on 1 January 2022 MiNA Therapeutics Limited ("MiNA" or the "Company"), the pioneer in small activating RNA (RNAa) therapeutics
Registration is disabled. '); }, success: function(response) { $('.megamenuthird[data-menu=' + $data_megamenu + '-articles]').html(response); }, error: function(xhr) { // if error occured $('.megamenuthird[data-menu=' + $data_megamenu + '-articles]').html("Error occured.please try again"); } }); } } //Child Level Menu Hover function get_childlevelmenu(currentid){ //console.log('current id '+currentid); var $currentelement = $('#'+currentid); $('.menu-item-'+$('#'+currentid).closest('.themegamenu').attr('cid').split('-')[3]).removeClass('defaultajax-...